mutations, in whom rituximab seems to get tiny added benefit.fifty nine Other genomic subgroups, including patients with BIRC3 This methylation profile is currently obtained for the MBL stage3 and stays somewhat secure after a while. On the other hand, some CLL have intratumor variability in spec